Clinical trials: Treatment Failure
End Stage Renal Disease, Chronic Kidney Diseases
Berinert (C1INH) vs Placebo for DGF/IRI
This is a Phase I/II double-blind, randomized, placebo-controlled study assessing safety and limited efficacy of intraoperative C1INH (500U/kidney) vs.
- Trial name
- NCT04696146
- Testing
- Berinert
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cedars-Sinai Medical Center
Premature Ovarian Failure
Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
The experimental focus of this project is on the interaction of DHEA treatment on pregnancy in women with open tubes, fertile male partners and evidence of premature ovarian failure.
- Trial name
- DHEAFert2 (NCT00948857)
- Testing
- Dehydroepiandrosterone
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- David H. Barad
Heart Failure, Diabetes
Dapagliflozin at Discharge on Hospital Heart Failure Readmission
This study will evaluate the safety and efficacy of dapagliflozin treatment in preventing hospital re-admissions, emergency room (ER) visits, urgent clinic visits, and death in patients with and without type 2 diabetes (T2D)…
- Trial name
- NCT04249778
- Testing
- Dapagliflozin
- Where
- 3 sites in United States
- Volunteers
- 105 people
- Sponsor
- Emory University
Coronary Artery Disease
An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
The purpose of this post approval study is to conduct a prospective, multicenter evaluation of the procedural and clinical outcomes of subjects that are treated with the commercially available Medtronic Resolute Integrity…
- Trial name
- RI-US (NCT01638507)
- Testing
- Resolute Integrity Stent
- Where
- United States
- Volunteers
- 230 people
- Sponsor
- Medtronic Vascular
Acute Respiratory Failure, Treatment With Noninvasive Positive Pressure Ventilation
Pilot Study of High-flow Humidified Nasal Oxygen During Breaks From Noninvasive Ventilation
The purpose of this study is to assess whether Optiflow, a high-flow humidified oxygen delivery system, is superior to standard oxygen therapy during breaks off noninvasive ventilation in patients affected by acute respiratory…
- Trial name
- OPTINIV (NCT01925534)
- Testing
- High-flow humidified nasal oxygen delivery system, Standard oxygen therapy
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Tufts Medical Center
HIV, AIDS
Resistance Testing to Improve Management of Virologic Failure in Sub-Saharan Africa
The study design is an open-label, randomized controlled trial. The study will be conducted at study sites in Uganda and South Africa.
- Trial name
- REVAMP (NCT02787499)
- Testing
- HIV-1 RNA Resistance Testing
- Where
- 2 sites in South Africa, Uganda
- Volunteers
- 840 people
- Sponsor
- Massachusetts General Hospital
HIV Infection
Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure
Many people with HIV fail to regain normal CD4 counts despite effectively suppressing HIV replication with medications. Blocking the "co-receptor" for HIV might decrease inflammation of the immune system, potentially providing an…
- Trial name
- NCT00735072
- Testing
- Maraviroc
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of California, San Francisco
Right Bundle-Branch Block, Heart Failure
Right Ventricular Septal Pacing in Patients With Right Bundle Branch Block and Heart Failure (The SPARK Trial)
This clinical study has been designed to test whether a new pacing therapy would lead to improvement in heart function, symptoms and quality of life in a specific group of heart failure patients.
- Trial name
- SPARK (NCT02441101)
- Testing
- RV DDD(R)-60 with AV optimization, RV DDD(R)-60
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Barry London
Heart Failure With Preserved Ejection Fraction (HFpEF)
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
This study evaluated the safety and tolerability of LCZ696 treatment in Japanese heart failure patients (NYHA Class II-IV) with preserved ejection fraction after CLCZ696D2301 (PARAGON-HF).
- Trial name
- NCT03909295
- Testing
- LCZ696
- Where
- 17 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Baroreflex Activation Therapy for Heart Failure
The purpose of this clinical trial (NCT02627196) is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy with the BAROSTIM NEO System in subjects with heart failure, defined as New…
- Trial name
- BeAT-HF (NCT02627196)
- Testing
- BAROSTIM NEO® System, Medical Management
- Where
- 92 sites in United States, United Kingdom
- Volunteers
- 1,090 people
- Sponsor
- CVRx, Inc.
Heart Failure With Reduced Ejection Fraction
HF Patients With LVADs Being Treated With SGLT2i
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
- Trial name
- NCT05278962
- Testing
- SGLT2i, No SGLT2i
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Chicago
Heart Failure, Ventricular Arrythmias
Safety and Efficacy of Automatic Testing Feature in New ICDs and CRT-Ds
This study is a prospective, non-randomized, multi-center clinical trial that will assess the safety and effectiveness of investigational models of the Promote™ RF CRT-D and Current™ RF ICD devices.
- Trial name
- NCT00746356
- Testing
- Testing of the autocapture features of the device
- Where
- 5 sites in United States
- Volunteers
- 128 people
- Sponsor
- Abbott Medical Devices
Aplastic Anemia, Neutropenia
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
Background: Severe aplastic anemia (SAA) can lead to problems with bone marrow health and result in low blood cell counts, which require frequent transfusions.
- Conditions
- Aplastic Anemia, Neutropenia, Pancytopenia, Severe Aplastic Anemia
- Trial name
- NCT01187017
- Testing
- Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Symptomatic Neurogenic Orthostatic Hypotension
Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension
To evaluate the time to treatment intervention in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Pure Autonomic Failure (PAF), Non-Diabetic Autonomic Neuropathy (NDAN) or Dopamine Beta Hydroxylase (DBH)…
- Trial name
- RESTORE (NCT02586623)
- Testing
- Droxidopa capsules
- Where
- 168 sites in United States
- Volunteers
- 453 people
- Sponsor
- H. Lundbeck A/S
Acute Respiratory Distress Syndrome, Critical Illness
Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery
Prospective multi-center phase 2b randomized placebo-controlled double-blinded interventional platform trial of two different pharmacologic therapies (intravenous Vitamin C or intravenous Acetaminophen) for patients with…
- Conditions
- Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis
- Trial name
- ASTER (NCT04291508)
- Testing
- Intravenous Acetaminophen (room temperature), Intravenous Vitamin C (refrigerated), 5% Dextrose (room temperature)
- Where
- 41 sites in United States
- Volunteers
- 488 people
- Sponsor
- Massachusetts General Hospital
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting
The primary purpose of the study was to describe the tolerability of treatment with the optimal dose of LCZ696 (97 mg sacubitril / 103 mg valsartan bid), over six (6) months, in patients with heart failure with reduced ejection…
- Trial name
- PARASAIL (NCT02690974)
- Testing
- LCZ696 (sacubitril/valsartan)
- Where
- 32 sites in Canada
- Volunteers
- 302 people
- Sponsor
- Novartis Pharmaceuticals
Hematologic Neoplasms, Multiple Myeloma
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
The purpose of this study is to look at whether the combination of lower-dose chemotherapy with two chemotherapy (anti-cancer) drugs, called busulfan and melphalan, and an antibody medication called alemtuzumab (Campath®), can…
- Conditions
- Hematologic Neoplasms, Multiple Myeloma, Anemia, Aplastic, Hemoglobinuria, Paroxysmal
- Trial name
- ALBUM (NCT00997386)
- Testing
- busulfan, and melphalan, and alemtuzumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Arizona
HIV Infections
Determining the Effects of Observed and Self-Administered Drug Regimens in HIV Infected Adults
Highly active antiretroviral therapy (HAART) has led to better health and survival rates among people with HIV/AIDS. The purpose of this study was to measure the effect of trained partner supervision when taking medication versus…
- Trial name
- NCT00608569
- Testing
- Lopinavir/ritonavir, Emtricitabine/Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate
- Where
- 9 sites in Botswana, Brazil and 6 more
- Volunteers
- 529 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
End-Stage Heart Failure, Bridge-to-Transplant LVAD Placement (BTT)
Development & Testing of a Decision Aid for LVAD Placement
The goal of this project is to develop a patient-centered decision aid for decision-making about end-stage heart failure treatment.
- Conditions
- End-Stage Heart Failure, Bridge-to-Transplant LVAD Placement (BTT), Destination Therapy LVAD Placement (DT), Refusal of LVAD Placement (Decliners)
- Trial name
- VADDA (NCT02248974)
- Testing
- LVAD Decision Aid
- Where
- 7 sites in United States
- Volunteers
- 98 people
- Sponsor
- Baylor College of Medicine
Heart Failure, ICD
Comparing Rate Response With CLS Versus Accelerometer ICD Settings in Heart Failure Patients With BIOTRONIK CRT-Ds
Dr. Jonathan Hsu and Dr. Eric Adler are conducting a research study to find out more about how implantable cardiac defibrillator (ICD) settings can be adjusted to improve patient cardiovascular health and quality of life.
- Conditions
- Heart Failure, ICD, Chronotropic Incompetence
- Trial name
- CLASS (NCT02693262)
- Testing
- CLS Mode on Biotronik CRT-D, Accelerometer Mode on Biotronik CRT-D
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego